Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis CapEx PPE: -$1,548M in FY2025, up 13.3% from a year earlier.
Latest, FY2025
-1,548
Period ended Dec 31, 2025
Change on a year earlier
+13.3%
-1,366 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Purchases of property, plant and equipment | -1 548 | -1 366”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CapEx PPE ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1,548 | +13.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | -1,366 | +28.9% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | -1,060 | +15.7% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | -916 | -33.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | -1,378 | +8.1% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | -1,275 | -7.5% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2019 | Dec 31, 2019 | -1,379 | – | Novartis Form 6-K (0001370368-21-000008) ↗ |
Cite this data
StockData. (2026). Novartis CapEx PPE ($M), annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-cf-capex-ppe
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.